Gino Turchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Gino Turchi has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Claudia Nesti
Molecular Medicine, IRCCS Stella Maris, Pisa, Italy
1 shared publication Francesca Trippi
1 shared publicationG. Alagona
1 shared publicationL. Pistelli
Department of Biorganic Chemistry, University of Pisa, Pisa, Italy
1 shared publicationLucia Migliore
1 shared publicationRoberto Scarpato
1 shared publication
Latest Publications
- 1 November 2009
- Published by Elsevier in Phytomedicine
- Vol. 16 (11) , 1014-1026
Protective activity of plicatin B against human LDL oxidation induced in metal ion-dependent and -independent processes. Experimental and theoretical studies
- 1 November 2009
- Published by Elsevier in Phytomedicine
- Vol. 16 (11) , 1014-1026
Protective activity of plicatin B against human LDL oxidation induced in metal ion-dependent and -independent processes. Experimental and theoretical studies
- Open Access
- 1 March 2000
- Published by Oxford University Press (OUP) in Mutagenesis
- Vol. 15 (2) , 143-147
Cytokinesis-block micronucleus assay in primary human liver fibroblasts exposed to griseofulvin and mitomycin C
Primary liver fibroblasts were applied in a cytokinesis-block micronucleus assay in combination with fluorescence in situ hybridization (FISH) using two protocols. In protocol A (Prot. A), cytochalasin B (Cyt B) was added at the end of the treatment time directly to the medium containing the standard compounds, whereas in protocol B (Prot. B) the chemical-containing medium was removed and fresh medium with Cyt B was added. The study was performed using the aneugen griseofulvin (GF) and the clastogen mitomycin C (MMC) as standard compounds. With both protocols GF induced a significant increase in MN frequency over controls in a dose-related manner at the lower concentrations tested (7.5 and 15 μg/ml). At the highest dose (30 μg/ml) the aneugen effect was substantially reduced. MN induction obtained with Prot. A was significantly higher (~3-fold) than with Prot. B at the most effective concentration. The aneugen effect induced by GF did not change when different cell densities were used, but again with Prot. A we obtained the highest effect. MN induced by MMC showed a dose- and time-dependent increase in both protocols. In contrast to GF, the greater clastogenic response induced by MMC in human liver fibroblasts was obtained with Prot. B, ~3-fold higher than Prot. A at the most effective concentration and ~2-fold with 24 h treatment at 0.17 μg/ml MMC. With GF, the FISH data in human liver fibroblasts (80% C+MN) were fairly consistent with those obtained in the rodent cell lines. In human whole blood cultures, the same dose used in our experiment produced a relatively higher percentage of C+MN. FISH analysis showed that MMC induced mainly MN containing acentric fragments rather than whole chromosomes. In conclusion we have demostrated that chemically induced genetic effects are strongly dependent on the cell culture employed, treatment schedule and intra- and post-treatment experimental conditions.
- 1 March 2000
- Published by Oxford University Press (OUP) in Mutagenesis
- Vol. 15 (2) , 143-147
Open AccessCytokinesis-block micronucleus assay in primary human liver fibroblasts exposed to griseofulvin and mitomycin C
Primary liver fibroblasts were applied in a cytokinesis-block micronucleus assay in combination with fluorescence in situ hybridization (FISH) using two protocols. In protocol A (Prot. A), cytochalasin B (Cyt B) was added at the end of the treatment time directly to the medium containing the standard compounds, whereas in protocol B (Prot. B) the chemical-containing medium was removed and fresh medium with Cyt B was added. The study was performed using the aneugen griseofulvin (GF) and the clastogen mitomycin C (MMC) as standard compounds. With both protocols GF induced a significant increase in MN frequency over controls in a dose-related manner at the lower concentrations tested (7.5 and 15 μg/ml). At the highest dose (30 μg/ml) the aneugen effect was substantially reduced. MN induction obtained with Prot. A was significantly higher (~3-fold) than with Prot. B at the most effective concentration. The aneugen effect induced by GF did not change when different cell densities were used, but again with Prot. A we obtained the highest effect. MN induced by MMC showed a dose- and time-dependent increase in both protocols. In contrast to GF, the greater clastogenic response induced by MMC in human liver fibroblasts was obtained with Prot. B, ~3-fold higher than Prot. A at the most effective concentration and ~2-fold with 24 h treatment at 0.17 μg/ml MMC. With GF, the FISH data in human liver fibroblasts (80% C+MN) were fairly consistent with those obtained in the rodent cell lines. In human whole blood cultures, the same dose used in our experiment produced a relatively higher percentage of C+MN. FISH analysis showed that MMC induced mainly MN containing acentric fragments rather than whole chromosomes. In conclusion we have demostrated that chemically induced genetic effects are strongly dependent on the cell culture employed, treatment schedule and intra- and post-treatment experimental conditions.